Latest Healthcare News

Page 9 of 197
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
Barramundi’s portfolio returned 3.0% on a gross basis in the September quarter, ahead of the ASX 200’s 1.3% gain. CSL, Ansell, MAAS Group and PWR Holdings led the recovery, although the NZX-listed investment company still traded at a 17.2% discount to NAV.
Victor Sage
Victor Sage
28 Oct 2026
Kingfish delivered a 10.2% gross return in the six months to September, but its shares ended the quarter at a 15.5% discount to NAV. The investment company also added Skellerup to its portfolio as Delegat, Vista and Fisher & Paykel Healthcare led quarterly gains.
Victor Sage
Victor Sage
28 Oct 2026
Singular Health has moved closer to a proposed A$3.5 million Florida Medicaid imaging repository while deploying 1,000 physician licences through its largest customer network. The September quarter also exposed the execution risks ahead, with the Florida MOU still subject to definitive agreements and the PNS contract due for renewal by year-end.
Victor Sage
Victor Sage
27 Oct 2026
NRW Holdings delivered record FY26 revenue and earnings after folding Fredon into a new EMIT division, while debt-funded expansion lifted leverage. The company enters FY27 with A$7.5 billion of secured work, a larger banking facility and a sharper test of whether diversification can keep converting into cash.
Victor Sage
Victor Sage
27 Oct 2026
Hydrix reported stronger contract momentum and launched a defence strategy in FY26, but revenue fell, cash burn increased and its statutory loss widened to $6.72 million. The auditor identified a material uncertainty over the company’s ability to continue as a going concern, despite a $5.2 million capital raising and planned debt conversions.
Sophie Babbage
Sophie Babbage
27 Oct 2026
Lumos Diagnostics has expanded FebriDx deployment to 265 US healthcare sites across 29 states, while product revenue rose 224% in the first quarter. The commercial gains came alongside a US$4.7 million operating cash outflow, slower-than-planned paediatric study enrolment and a Hologic development timeline pushed to around June 2028.
Ada Torres
Ada Torres
27 Oct 2026
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
Alcidion will launch an on-market buy-back of up to 10% of its issued shares, giving the healthcare software company another way to deploy capital as cash generation improves. The maximum is a capacity, not a commitment, with purchases expected to be selective.
Victor Sage
Victor Sage
27 Oct 2026
Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.
Ada Torres
Ada Torres
27 Oct 2026
Mach7 Technologies has delivered its first positive first-quarter operating cash flow, while ARR rose 8.5% in constant currency to A$23.5 million. The next test is whether increased product investment and the Flamingo rollout can translate into contracted sales.
Victor Sage
Victor Sage
26 Oct 2026
Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.
Victor Sage
Victor Sage
26 Oct 2026

Browse the archive

Full archive